A multi-center, randomized controlled clinical trial of the application of a shortened protocol of long-acting Triptorelin down-regulated prior to IVF/ICSI among patients with endometriosis: A protocol

What Was Tested

This randomized controlled trial paper looks at Triptorelin in the context of endometriosis.

Endometriosis is the major cause of progressive pelvic pain and subfertility.

Endometriosis is a classic indication for IVF.

Who Took Part

The abstract describes 421 participants taking part.

By PubMed's age tags, the people studied were adults, women only.

Eligible and consenting women will be randomly assigned to one of two treatments (one cycle of a GnRH agonist or two cycles of a GnRH agonist) prior to IVF/ICSI using a table of random numbers.

The sample size of this trial is estimated to be 421 participants for each of the two arms.

How the Study Was Run

In design terms this was a randomized and single-blind study.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Triptorelin study one party knew the assignments and the other did not.

The primary outcome of this trial is clinical pregnancy rate.

Appropriate interim analyses will be conducted by a data monitoring and ethics committee (DMEC), and the final test will be an intention-to-treat analysis.

What Was Measured

Topics PubMed links to this paper include Birth Rate, Endometriosis, Infertility, Luteolytic Agents, Pregnancy Rate, Sperm Injections, Intracytoplasmic and Triptorelin Pamoate.

What This Means in Plain Language

The paper is a randomized and single-blind study of Triptorelin in 421 participants in people with endometriosis.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2018 (Reproductive health), a journal based in England.

More context: the Triptorelin compound page, Endometriosis research.